Aims and scope
Clinical and Molecular Allergy is an open access, peer-reviewed, international journal that covers all aspects of allergy research with a primary focus on molecular allergy and clinical applications of molecular techniques. Clinical and Molecular Allergy is the official journal of the Italian Society of Allergology, Asthma and Clinical Immunology.
This international journal appeals to allergists & immunologists, pulmonologists, otolaryngologists, geneticists and other physicians, healthcare workers, medical students and the public worldwide.
Topics of interest include, but are not limited to:
- Clinical allergy, including respiratory allergy, food allergy, drug allergy, insect sting allergy
- Diagnostics (component resolved diagnostics, allergen extract diagnostics)
- Structural biology of allergens (and their interactions with the immune system)
- Bioinformatics of allergens
- Epitopes and mimotopes
- Genetics and epigenetics
- Therapeutics using molecular techniques
- Effect of the microbiome on development of allergic disease
The journal accepts research articles, reviews, commentaries, case reports and correspondence and has six different sections:
- Allergen Immunotherapy
- Clinical and Molecular Allergy
- Clinical Immunology
- Food, Drug, Insect Allergy
- Respiratory Allergy
All articles published by Clinical and Molecular Allergy are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Clinical and Molecular Allergy you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Clinical and Molecular Allergy therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Clinical and Molecular Allergy are included in:
- Global Health
- PubMed Central
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
We are working closely with relevant indexing services including Web of Science (Thomson Reuters) to ensure that articles published in Clinical and Molecular Allergy will be available in their databases when appropriate.
Clinical and Molecular Allergy operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Manuscripts are initially screened by the Editor-in-Chief, Deputy Editor or relevant Section Editor and suitable manuscripts are sent to at least peer reviewers for consideration. Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Clinical and Molecular Allergy should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Clinical and Molecular Allergy
Articles in Clinical and Molecular Allergy should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Clin Mol Allergy [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Mol Allergy 2009, 1:115. refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Clinical and Molecular Allergy
Clinical and Molecular Allergy's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Clinical and Molecular Allergy offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Clinical and Molecular Allergy gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Clinical and Molecular Allergy are included in article alerts and regular email updates. Some may be highlighted on Clinical and Molecular Allergy’s pages and on the BioMed Central homepage.
In addition, articles published in Clinical and Molecular Allergy may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical and Molecular Allergy. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Clinical and Molecular Allergy you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.